Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,142.50 +2,063.86 (+3.32%) CMC Crypto 200
1,371.97 +59.34 (+4.52%)
TScan Therapeutics, Inc. (TCRX)
After hours:
| Previous close | 6.92 |
| Open | 6.82 |
| Bid | 6.77 x 200 |
| Ask | 6.86 x 100 |
| Day's range | 6.71 - 7.13 |
| 52-week range | 1.62 - 9.00 |
| Volume | |
| Avg. volume | 193,598 |
| Market cap | 343.573M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.60 |
GlobeNewswireTScan Therapeutics Announces Closing of Upsized Public Offering
WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasd
- GlobeNewswire
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting comm
- GlobeNewswire
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase share
